NCT04703101View on ClinicalTrials.gov

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2026

Conditions
Locally Advanced Rectal CarcinomaRectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage IIA Rectal Cancer AJCC v8Stage IIB Rectal Cancer AJCC v8Stage IIC Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8
Interventions
DRUG

Capecitabine

Given IV

DRUG

Fluorouracil

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

DRUG

Leucovorin

Given IV

DRUG

Oxaliplatin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

BEHAVIORAL

Surveillance

Undergo NOM

PROCEDURE

Total Mesorectal Excision

Undergo TME

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Natera, Inc.
All Listed Sponsors
collaborator

The Joseph Drown Foundation

UNKNOWN

collaborator

Natera, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT04703101 - Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | Biotech Hunter | Biotech Hunter